{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:28Z","timestamp":1794047488166,"version":"4.8.0"},"reference-count":14,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.286409","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:41:02Z","timestamp":1733370062000},"page":"1182-1186","source":"Crossref","is-referenced-by-count":1,"title":["Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single-center, real-world experience"],"prefix":"10.3324","volume":"110","author":[{"given":"Ke","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Agbuduwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickolaos","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Sive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agapi","family":"Parcharidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"75091","doi-asserted-by":"crossref","unstructured":"Agbuduwe C, Iqbal G, Cairns D. Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials. Blood Adv. 2022; 6(17):5113-5123.","DOI":"10.1182\/bloodadvances.2022007608"},{"key":"75092","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021; 397(10272):410-427.","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"75093","doi-asserted-by":"crossref","unstructured":"He JS, Yue XY, He DH. Multiple Extramedullary-bone related and\/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma. Front Oncol. 2021; 11:668099.","DOI":"10.3389\/fonc.2021.668099"},{"key":"75094","doi-asserted-by":"crossref","unstructured":"Montefusco V, Gay F, Spada S. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica. 2020; 105(1):193-200.","DOI":"10.3324\/haematol.2019.219139"},{"key":"75095","unstructured":"Gagelmann N, Eikema DJ, Iacobelli S. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018; 103(5):890-897."},{"key":"75096","doi-asserted-by":"crossref","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010; 21(2):325-330.","DOI":"10.1093\/annonc\/mdp329"},{"key":"75097","doi-asserted-by":"crossref","unstructured":"Pour L, Sevcikova S, Greslikova H. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014; 99(2):360-364.","DOI":"10.3324\/haematol.2013.094409"},{"key":"75098","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Heuck C, Mitchell A. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012; 97(11):1761-1767.","DOI":"10.3324\/haematol.2012.065698"},{"key":"75099","doi-asserted-by":"crossref","unstructured":"Weinstock M, Aljawai Y, Morgan EA. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015; 169(6):851-858.","DOI":"10.1111\/bjh.13383"},{"key":"75100","doi-asserted-by":"crossref","unstructured":"Blad\u00e9 J, Fern\u00e1ndez De Larrea C, Rosi\u00f1ol L, Cibeira MT, Jim\u00e9nez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011; 29(28):3805-3812.","DOI":"10.1200\/JCO.2011.34.9290"},{"key":"75101","doi-asserted-by":"crossref","unstructured":"Besse L, Sedlarikova L, Greslikova H. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016; 97(1):93-100.","DOI":"10.1111\/ejh.12688"},{"key":"75102","doi-asserted-by":"crossref","unstructured":"Richardson PG, Trudel S, Popat R. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med. 2023; 389(11):1009-1022.","DOI":"10.1056\/NEJMoa2303194"},{"key":"75103","doi-asserted-by":"crossref","unstructured":"Richardson PG, Bringhen S, Voorhees P. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1\u20132 study. Lancet Haematol. 2020; 7(5):e395-e407.","DOI":"10.1016\/S2352-3026(20)30044-2"},{"key":"75104","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Richardson P, Lonial S. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022; 22(7):460-473.","DOI":"10.1016\/j.clml.2022.01.011"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11864\/77875","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11864\/78334","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11864\/77875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:47Z","timestamp":1794046067000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286409","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}